Cynata posts flat Phase 2 CYP‑001 GvHD data
Cynata Therapeutics (ASX:CYP) reported primary evaluation results from its Phase 2 trial of CYP‑001 in high‑risk acute graft versus host disease, showing no significant difference in response rates compared with the control group.

_1422921_640x360_2503887427674-640x360.webp&w=3840&q=75)
_1422906_640x360_2503881283728-640x360.webp&w=3840&q=75)


_1422893_640x360_2503875651749-640x360.webp&w=3840&q=75)





_1422875_640x360_2503875139565-640x360.webp&w=3840&q=75)